

Haematologica
HAEMATOL/2019/216028
Version 3

Complement C3 inhibition by compstatin Cp40 prevents intra- and
extravascular hemolysis of red blood cells

Inge Baas, Laura Delvasto-Nuñez/, Peter Ligthart, Conny Brouwer,
Claudia Folman, Edimara S. Reis, Daniel Ricklin, John D. Lambris,
Diana Wouters, Masja de Haas, Ilse Jongerius, and Sacha S. Zeerleder

Disclosures: J.D.L. is the founder of Amyndas Pharmaceuticals, which is developing complement inhibitors (including third-generation Compstatin analogs such as AMY-101) and inventor of patents or patent applications that describe the use of complement inhibitors for therapeutic purposes, some of which are developed by Amyndas Pharmaceuticals. J.D.L. is also the inventor of the Compstatin technology licensed to Apellis Pharmaceuticals (i.e., 4(1MeW)7W/POT-4/APL-1 and PEGylated derivatives). D.R. is a co-inventor on patents or patent applications describing Compstatin analogs and their clinical use. The remaining authors declare no competing financial interest.

Contributions: I.B. and L.D.N. performed experiments. S.S.Z., D.W., M.H., designed the research and wrote the paper. L.D.N., I.B. and I.J. analyzed the results and wrote the manuscript. P.L., C.B., C.F. collected samples and provided information about these samples. E.S.R, D.R., J.D.L. provided Cp40 and a Cp40 control peptide and contributed to the design, analysis and interpretation of the study.